Profile data is unavailable for this security.
About the company
Magforce AG is a Germany-based company engaged in the provision of nanotechnology solutions for health sector. Its non-invasive technology uses magnetic nanoparticles to combat tumors, without harmful effect on the healthy tissues. The Company's range of treatment products includes NanoTherm Therapie for treating tumors locally; NanoTherm, a fluid containing ferrous oxide molecules that penetrate deeply into the tumor tissues and reacting to the presence of a magnetic field; NanoActivator, which are iron oxide nanoparticles for tumors in all areas of the body, and NanoPlan, a software platform that facilitates therapy planning and adjusts proper temperatures for the treatment and and the necessary magnetic field strength. As of December 31, 2011, Nanostart AG held a 49.6%-stake in the Company.
- Revenue in EUR (TTM)351.98k
- Net income in EUR-10.57m
- Incorporated2005
- Employees69.00
- LocationMagforce AGMax-Planck-Strasse 3BERLIN 12489GermanyDEU
- Phone+49 303083800
- Fax+49 3 030838099
- Websitehttps://www.magforce.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neovacs SA | 533.41k | -8.74m | 51.54k | 22.00 | -- | 0.00009 | -- | 0.0966 | -30,639.66 | -30,639.66 | 1.52 | 138.89 | 0.0099 | -- | 1.84 | 24,245.91 | -16.21 | -24.42 | -17.66 | -28.28 | 5.50 | -232.13 | -1,639.16 | -6,444.71 | -- | -- | 0.0131 | -- | 47,954.95 | -- | -146.40 | -- | 82.72 | -- |
MagForce AG | 351.98k | -10.57m | 59.86k | 69.00 | -- | 0.0022 | -- | 0.1701 | -0.3531 | -0.3531 | 0.0118 | 0.8967 | 0.0055 | 3.47 | 0.8532 | 5,101.16 | -16.47 | -3.78 | -31.53 | -6.78 | -89.95 | 25.30 | -3,004.22 | -295.23 | 0.0321 | -1.97 | 0.2485 | -- | -43.33 | -5.77 | -171.71 | -- | -- | -- |
European Institute of Science AB | 59.12k | -237.47k | 121.06k | 2.00 | -- | 1.35 | -- | 2.05 | -4.23 | -4.23 | 1.05 | 1.93 | 0.2438 | 1.24 | 9.47 | 343,435.00 | -97.95 | -93.04 | -105.15 | -103.14 | 59.32 | 66.99 | -401.71 | -518.86 | 5.70 | -- | 0.00 | -- | 13.66 | 8.54 | 0.3974 | -- | -- | -- |
Paion AG | -100.00bn | -100.00bn | 158.37k | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |